9 research outputs found
MODAL PROPERTIES AND FREE VIBRATION OF UPLIFTING BEHAVIOR OF MULTISTORY BUILDINGS MODELED AS UNIFORM SHEAR-BEAM
THREE-DIMENSIONAL SHAKING TABLE TESTS ON SEISMIC RESPONSE OF REDUCED-SCALE STEEL FRAMES WITH YIELDING BASE PLATES ALLOWED TO UPLIFT
THREE-DIMENSIONAL SEISMIC RESPONSE OF TEN-STORY STEEL FRAMES WITH YIELDING BASE PLATES ALLOWED TO UPLIFT
SHAKING TABLE TEST OF ROCKING-CONTROLLED WOODEN WALL WITH COLUMN-BASE ALLOWED UPLIFT BEHAVIOR
HYSTERETIC CHARACTERISTICS AND PLASTIC DEFORMATION CAPACITY OF UPLIFT YIELDING BASE-PLATES FOR CONTROLLED ROCKING FRAMES
Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
Abstract Background and Aim Although tenofovir alafenamide (TAF), as well as entecavir (ETV), is widely used as firstâline treatment for patients with chronic hepatitis B, there are only a few studies comparing sequential therapy from ETV to TAF and continuous ETV monotherapy in patients with maintained virologic response to ETV. Methods In a retrospective multicenter study, we investigated the efficacy and safety of sequential therapy from ETV to TAF (ETVâTAF group) and compared them with continuous ETV monotherapy (ETV group), using propensity score matching, in chronic hepatitis B patients. Results From 442 patients, we analyzed 142 patients from each group comprising 71 patients matched for several data, including age, HBV genotype, hepatitis B envelope antigen, cirrhosis, alanine aminotransferase, platelet count, prior ETV monotherapy period, and hepatitis B surface antigen (HBsAg) change during prior ETV monotherapy. In the ETVâTAF group, HBsAg levels significantly decreased from baseline to 48âweeks after switching to TAF (â0.02 log IU/mL, P = 0.038). HBcrAg levels also significantly decreased after switching to TAF (â0.1 log IU/mL, P = 0.004). However, there were no significant differences in the reduction of HBsAg and HBcrAg levels between the ETVâTAF and ETV groups. There was no significant difference in the change of estimated glomerular filtration rate levels from baseline to 48âweeks between the two groups. Conclusions The present study indicated that the efficacy, especially of the HBsAgâreducing action, and safety of sequential therapy from ETV to TAF were similar to those of continuous ETV monotherapy among chronic hepatitis B patients with maintained virologic response to ETV